About My Health Careers Internship MedBlogs Contact us

GlaxoSmithKline and AstraZeneca Drugs Show Promise In Clinical Trials For Lupus

by Shirley Johanna on November 11, 2015 at 6:53 PM
Font : A-A+

GlaxoSmithKline and AstraZeneca Drugs Show Promise In Clinical Trials For Lupus

Two drugs from GlaxoSmithKline and AstraZeneca have shown promise in systemic lupus erythematosus (SLE), raising the hope of improved treatment for the debilitating disease.

Lupus is an autoimmune disorder that is characterized by joint pain and swelling, rashes on the skin and extreme fatigue. Some patients experience intermittent flare-ups that can lead to severe and even life-threatening symptoms.


GSK reported new phase III data on a new subcutaneous formulation of its market-leading Benlysta (belimumab) product that is the first new therapy for the disease in five decades.

In the phase III trial, a 200mg subcutaneous dose of the B-lymphocyte stimulator (BLyS) inhibitor given once a week was found to be more effective in reducing disease activity compared to placebo.

After a year, 61% of the Benlysta group showed reduced disease activity as measured by the SLE Responder Index (SRI) - a standard measure if efficacy - compared to 48% of patients on placebo.

"On the basis of these data, we expect to progress towards global regulatory filings for a belimumab subcutaneous formulation," commented Paul-Peter Tak, head of immuno-inflammation R&D at GSK.

A new phase II trial conducted by AZ on the drug - called anifrolumab (formerly MEDI-546) - is an antibody blocking the type I interferon (IFN) receptor, showed that the drug significantly reduced disease activity and improved symptoms of SLE, including rash and arthritis.

After a year, 51.5% of patients taking a 300mg intravenous dose of anifrolumab once a month achieved an SRI response, compared to 17% of the placebo group.

"The lupus community has been disappointed too often with clinical trial results," commented principal investigator Richard Furie of North Shore-LIJ Health System. "We have been eagerly awaiting clinical data of this magnitude for many years," he added.

Source: Medindia

News A-Z
News Category
What's New on Medindia
Printed Temperature Sensors help with Continuous Temperature Monitoring
Health Benefits of Giloy
Breast Cancer Awareness Month 2021 - It's time to RISE
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Clinical Trials Clinical Trials - The Past and The Future Clinical Trials - Different Phases of the trial Top Ten Selling Drugs Drugs Banned in India Placebo Effects: Rare Insights Aplastic Anemia 

Recommended Reading
Black Women at a Greater Risk of Developing Lupus, Study
Young black women are at a much greater risk of getting affected by lupus during their childbearing ...
Plant Extract may Lead to Development of New Drugs for Lupus
Researchers at University of Houston (UH) are currently analyzing the effectiveness of a plant ......
Gene Variants That May Cause Kidney Problems in Lupus Patients Discovered
Scientists have identified gene variants that are linked with an increased risk for kidney ......
How and When to Stop Immunosuppressants in Lupus Patients
Immunosuppressant therapy can be successfully stopped for majority of lupus patients who are in ......
Aplastic Anemia
Aplastic anemia (AA) is a term that refers to a condition where the body fails to produce enough blo...
Clinical Trials
Clinical trials are experiments that yield useful information to clinicians if a particular treatmen...
Clinical Trials - Different Phases of the trial
Clinical trials serve as a vital component for improving the treatment of medical conditions as they...
Clinical Trials - The Past and The Future
Many of the drugs that are used today have been discovered by chance or often by mere serendipity...
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Drugs Banned in India
Several drugs are either banned or withdrawn after introduction in the market....
Placebo Effects: Rare Insights
Placebo response is now generally well accepted. ‘Placebo response’ is the friend of the clinician a...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use